Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population-level effectiveness of pre-exposure prophylaxis for HIV prevention among men who have sex with men in Montréal (Canada): a modelling study of surveillance and survey data.
Doyle CM, Milwid RM, Cox J, Xia Y, Lambert G, Tremblay C, Otis J, Boily MC, Baril JG, Thomas R, Blais AD, Trottier B, Grace D, Moore DM, Mishra S, Maheu-Giroux M. Doyle CM, et al. Among authors: baril jg. J Int AIDS Soc. 2023 Dec;26(12):e26194. doi: 10.1002/jia2.26194. J Int AIDS Soc. 2023. PMID: 38054579 Free PMC article.
High rates of forward transmission events after acute/early HIV-1 infection.
Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, Baril JG, Thomas R, Rouleau D, Bruneau J, Leblanc R, Legault M, Tremblay C, Charest H, Wainberg MA; Quebec Primary HIV Infection Study Group. Brenner BG, et al. Among authors: baril jg. J Infect Dis. 2007 Apr 1;195(7):951-9. doi: 10.1086/512088. Epub 2007 Feb 16. J Infect Dis. 2007. PMID: 17330784
Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.
Loutfy MR, Ackad N, Antoniou T, Baril JG, Conway B, de Wet J, Trottier B, Kovacs CM, Thompson W, Martel AY, Trottier S, Rouleau D, Shafran SD, Rachlis A, Fraser C, Smaill F, Walmsley SL, Tseng AL, Sampalis JS. Loutfy MR, et al. Among authors: baril jg. HIV Clin Trials. 2007 Sep-Oct;8(5):259-68. doi: 10.1310/hct0805-259. HIV Clin Trials. 2007. PMID: 17956827 Clinical Trial.
Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals.
Côté P, Baril JG, Hébert MN, Klein M, Lalonde R, Poliquin M, Rouleau D, Therrien R, Vézina S, Willems B, Dion H, Junod P, Lapointe N, Lévesque D, Pinault L, Tremblay C, Trottier B, Trottier S, Tsoukas C, Piché A. Côté P, et al. Among authors: baril jg. Can J Infect Dis Med Microbiol. 2007 Sep;18(5):293-303. doi: 10.1155/2007/631054. Can J Infect Dis Med Microbiol. 2007. PMID: 18923731 Free PMC article.
Changes in function of HIV-specific T-cell responses with increasing time from infection.
Ndongala ML, Kamya P, Boulet S, Peretz Y, Rouleau D, Tremblay C, Leblanc R, Côté P, Baril JG, Thomas R, Vézina S, Boulassel MR, Routy JP, Sékaly RP, Bernard NF. Ndongala ML, et al. Among authors: baril jg. Viral Immunol. 2010 Apr;23(2):159-68. doi: 10.1089/vim.2009.0084. Viral Immunol. 2010. PMID: 20373996 Free PMC article.
Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57.
Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Côté P, Boulassel MR, Baril JG, Kovacs C, Migueles SA, Connors M, Suscovich TJ, Brander C, Tremblay CL, Bernard N; Canadian Cohort of HIV Infected Slow Progressors. Kamya P, et al. Among authors: baril jg. J Virol. 2011 Jun;85(12):5949-60. doi: 10.1128/JVI.02652-10. Epub 2011 Apr 6. J Virol. 2011. PMID: 21471235 Free PMC article.
115 results